These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27272956)

  • 1. Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse.
    Jongen PJ; Stavrakaki I; Voet B; Hoogervorst E; van Munster E; Linssen WH; Sinnige LG; Verhagen WI; Visser LH; van der Kruijk R; Verheul F; Boringa J; Heerings M; Gladdines W; Lönnqvist F; Gaillard P
    J Neurol; 2016 Aug; 263(8):1641-51. PubMed ID: 27272956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.
    Zivadinov R; Rudick RA; De Masi R; Nasuelli D; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
    Neurology; 2001 Oct; 57(7):1239-47. PubMed ID: 11591843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
    Zivadinov R; Zorzon M; De Masi R; Nasuelli D; Cazzato G
    J Neurol Sci; 2008 Apr; 267(1-2):28-35. PubMed ID: 17945260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous Methylprednisolone-Induced Nocturnal Sinus Bradycardia in a Multiple Sclerosis Patient.
    Osuagwu F; Jahnke B
    Prim Care Companion CNS Disord; 2016; 18(2):. PubMed ID: 27486530
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis.
    Perumal JS; Caon C; Hreha S; Zabad R; Tselis A; Lisak R; Khan O
    Eur J Neurol; 2008 Jul; 15(7):677-80. PubMed ID: 18459972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of high-dose intravenous methyl-prednisolone treatment on intraocular pressure in multiple sclerosis patients with relapse.
    Acar M; Gedizlioglu M; Koskderelioglu A; Ozturk F; Kilinc S; Talay N
    Eur Neurol; 2012; 68(1):20-2. PubMed ID: 22677889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Home administration of intravenous methylprednisolone for multiple sclerosis relapses: the experience of French multiple sclerosis networks.
    Créange A; Debouverie M; Jaillon-Rivière V; Taithe F; Liban D; Moutereau A; Clavelou P; Defer G
    Mult Scler; 2009 Sep; 15(9):1085-91. PubMed ID: 19556312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
    Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
    Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term safety of pulse steroid therapy in multiple sclerosis relapses.
    Shaygannejad V; Ashtari F; Alinaghian M; Norouzi R; Salari M; Fatehi F
    Clin Neuropharmacol; 2013; 36(1):1-3. PubMed ID: 23334067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
    Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
    Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
    Le Page E; Veillard D; Laplaud DA; Hamonic S; Wardi R; Lebrun C; Zagnoli F; Wiertlewski S; Deburghgraeve V; Coustans M; Edan G; ;
    Lancet; 2015 Sep; 386(9997):974-81. PubMed ID: 26135706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effects of methylprednisolone on cerebral volume in multiple sclerosis relapses.
    Chapman C; Tubridy N; Cook MJ; Mitchell PJ; MacGregor LR; Lovelock C; Litewka L; Sedal L; Kilpatrick TJ; Butzkueven H
    J Clin Neurosci; 2006 Jul; 13(6):636-8. PubMed ID: 16790352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response.
    Evangelopoulos ME; Nasiri-Ansari N; Kassi E; Papadopoulou A; Evangelopoulos DS; Moutsatsou P
    Sci Rep; 2021 Sep; 11(1):19462. PubMed ID: 34593869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
    De Stefano N; Filippi M; Hawkins C;
    J Neurol Sci; 2008 Mar; 266(1-2):44-50. PubMed ID: 17897678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylprednisolone-induced Toxic Hepatitis After Intravenous Pulsed Therapy for Multiple Sclerosis Relapses.
    Ferraro D; Mirante VG; Losi L; Villa E; Simone AM; Vitetta F; Federzoni L; Nichelli PF; Sola P
    Neurologist; 2015 Jun; 19(6):153-4. PubMed ID: 26075468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis.
    Nos C; Sastre-Garriga J; Borràs C; Río J; Tintoré M; Montalban X
    Mult Scler; 2004 Aug; 10(4):413-6. PubMed ID: 15327039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genes differentially expressed by methylprednisolone in vivo in CD4 T lymphocytes from multiple sclerosis patients: potential biomarkers.
    De Andres C; García MI; Goicoechea H; Martínez-Ginés ML; García-Domínguez JM; Martín ML; Romero-Delgado F; Benguría A; Sanjurjo M; López-Fernández LA
    Pharmacogenomics J; 2018 Jan; 18(1):98-105. PubMed ID: 27670768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy.
    Riedl M; Kolbe E; Kampmann E; Krämer I; Kahaly GJ
    J Endocrinol Invest; 2015 Feb; 38(2):177-82. PubMed ID: 25576458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.